Theriva Biologics, Inc. (TOVX)
NYSEAMERICAN: TOVX · Real-Time Price · USD
0.2251
+0.0001 (0.04%)
Oct 2, 2026, 4:00 PM EDT - Market closed
Theriva Biologics Employees
As of December 31, 2025, Theriva Biologics had 16 total employees, including 15 full-time and 1 part-time employees. The number of employees decreased by 6 or -27.27% compared to the previous year.
Employees
16
Change (1Y)
-6
Growth (1Y)
-27.27%
Revenue / Employee
$18,750
Profits / Employee
-$820,500
Market Cap
10.33M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 16 | -6 | -27.27% | 15 | 1 |
| Dec 31, 2024 | 22 | 0 | - | 20 | 2 |
| Dec 31, 2023 | 22 | 1 | 4.76% | 22 | 0 |
| Dec 31, 2022 | 21 | 5 | 31.25% | 21 | 0 |
| Dec 31, 2021 | 16 | 6 | 60.00% | 16 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 42 |
| Senti Biosciences Holdings | 39 |
| Moleculin Biotech | 17 |
| CalciMedica | 15 |
| BioVie | 13 |
| Purple Biotech | 10 |
| MetaVia | 8 |
| Intensity Therapeutics | 7 |
TOVX News
- 2 days ago - Theriva Biologics announces results from VIRAGE Phase 2b trial of VCN-01 - TheFly
- 2 days ago - Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine - GlobeNewsWire
- 7 weeks ago - Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results - GlobeNewsWire
- 7 weeks ago - Theriva Biologics Earnings release: Q2 2026 - Filings
- 7 weeks ago - Theriva Biologics Quarterly report: Q2 2026 - Filings
- 1 month ago - Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma - GlobeNewsWire
- 2 months ago - Theriva Biologics gets regulatory authorization to proceed with VIRAGE2 in Spain - TheFly
- 2 months ago - Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma - GlobeNewsWire